Werewolf Therapeutics and Ambros Therapeutics entered a definitive merger agreement that pairs the CRPS-1 drug neridronate with a public listing path, alongside an oversubscribed $150 million private placement. The combined company will operate as Ambros Therapeutics and is expected to trade on Nasdaq under AMBX after deal close. The transaction is designed to fund the next regulatory push, with the proceeds expected to support topline data from the pivotal CRPS-RISE Phase III trial (NCT07210515). Neridronate has received Breakthrough Therapy, Fast Track and Orphan Drug designations. For investors and the rare-disease drug community, the structure reflects a growing strategy among smaller biotechs to gain market access via merger with a listing vehicle rather than a traditional IPO.